{"success":true,"data":{"pressRelease":{"id":"18991","rtpr_id":"nBw6PjTCra","ticker":"ALNY","exchange":"NASDAQ","all_tickers":["ALNY"],"title":"Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM","author":"Business Wire","published_at":"2026-05-04T12:30:00.404Z","article_body":"Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent\nClinical Profile of Vutrisiran in ATTR-CM\n\nAlnylam Pharmaceuticals, Inc\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.alnylam.com%2F&esheet=54527665&newsitemid=20260504658209&lan=en-US&anchor=Alnylam+Pharmaceuticals%2C+Inc&index=1&md5=4b0af1fd4bf6f61a946eacc825deeeb9)\n. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it\nwill present new data analyses for vutrisiran in patients with the\ncardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis\n(ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society\nof Cardiology, taking place May 9-12, 2026, in Barcelona, Spain.\n\nATTR-CM is a heterogeneous and rapidly progressive disease, and patients often\npresent with complex clinical profiles. At Heart Failure 2026, Alnylam will\npresent multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran,\nwhich continue to support its use as a first-line treatment for patients with\nATTR-CM, and further characterize its clinical profile across patients with a\nhigh disease burden, and in the context of concomitant therapies. Vutrisiran\nis the first and only transthyretin (TTR) silencer for ATTR-CM that delivers\nrapid knockdown of TTR at the source.\n\nAdditional analyses being presented at the congress include a pharmacodynamic\nanalysis of TTR knockdown with vutrisiran across subgroups, a pooled safety\nanalysis evaluating the incidence of TTR lowering with vitamin-A-related\noutcomes across clinical trial and real-world datasets, as well as the design\nof DemonsTTRate, a global, long-term observational study evaluating real-world\nuse in patients with ATTR-CM.\n\nPresentation Details\n\nDesign and Rationale of DemonsTTRate: A Global, Long-Term Observational Study\nto Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with\nCardiomyopathy \n\nSession: Evolving management of cardiomyopathies: early detection, precision\ndiagnostics, and emerging treatments (Moderated ePosters 3)\n\nSunday, May 10, 08:30 – 09:15 CEST, 2:30 – 3:15 A.M. EST\n\nPresenting Author: Pablo Garcia-Pavia, Spain\n\nInfluence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: Insights From\nHELIOS-B \n\nSession: Cardiac amyloidosis: therapeutic strategies and clinical outcomes\n(Moderated ePosters 4)\n\nSunday, May 10, 15:30 – 16:15 CEST, 9:30 – 10:15 A.M. EST\n\nPresenting Author: Awais Sheikh, United Kingdom\n\nEffect of Vutrisiran in Patients with and without Atrial Fibrillation or\nFlutter: Analysis from HELIOS-B \n\nSession: Advances in amyloidosis and hypertrophic cardiomyopathy: from\ndiagnosis to treatment (Moderated ePosters 2)\n\nMonday, May 11, 10:30 – 11:15 CEST, 4:30 – 5:15 A.M. EST\n\nPresenting Author: Xiaowen Wang, United States of America\n\nTreatment with Transthyretin-Lowering RNA Interference Therapeutics is Not\nAssociated with Ocular or Other Clinical Events Due to Vitamin A Reduction:\nPooled Analysis of Vutrisiran and Patisiran Data \n\nSession: Advances in amyloidosis and hypertrophic cardiomyopathy: from\ndiagnosis to treatment (Moderated ePosters 2)\n\nMonday, May 11, 10:30 – 11:15 CEST, 4:30 – 5:15 A.M. EST\n\nPresenting Author: Mathew Maurer, United States of America\n\nVutrisiran-Mediated Knockdown of Transthyretin in Patients with Transthyretin\nAmyloidosis \n\nSession: Transthyretin amyloidosis: long-term outcomes and emerging therapies\n(Rapid Fire Abstracts)\n\nMonday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST\n\nPresenting Author: Vincent Algalarrondo, France\n\nInfluence of Disease-Modifying Therapy on the Effectiveness of Vutrisiran in\nTransthyretin Cardiac Amyloidosis \n\nSession: Transthyretin amyloidosis: long-term outcomes and emerging therapies\n(Rapid Fire Abstracts)\n\nMonday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST\n\nPresenting Author: Arielle Abovich, United States of America\n\nConsistent Efficacy of Vutrisiran Across Sexes in ATTR-CM, HELIOS-B Trial\n–Prespecified Sex Analysis \n\nSession: Transthyretin amyloidosis: long-term outcomes and emerging therapies\n(Rapid Fire Abstracts)\n\nMonday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST\n\nPresenting Author: Josephine Mansell, United Kingdom\n\nComorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights\nFrom the HELIOS-B Trial \n\nSession: Risk factors and comorbidities (Moderated ePosters 3)\n\nTuesday, May 12, 08:30 to 09:15 CEST, 2:30 – 3:15 A.M. EST\n\nPresenting Author: Sarah Birkhoelzer, United Kingdom\n\nAMVUTTRA(®) (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION\n\nIndications \n\nIn the EU, AMVUTTRA(®) (vutrisiran) is indicated for the treatment of:\n\n\n * hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2\npolyneuropathy (hATTR-PN).\n\n * wild-type or hereditary transthyretin amyloidosis in adult patients with\ncardiomyopathy (ATTR-CM).\n\nAvailability across the EU is subject to local reimbursement timelines.\n\nImportant Safety Information \n\nReduced Serum Vitamin A Levels and Recommended Supplementation \n\nVutrisiran treatment leads to a decrease in serum vitamin A levels.\nSupplementation of approximately, but not exceeding, 2500 IU to 3000 IU\nvitamin A per day is advised for patients taking vutrisiran. Patients should\nbe referred to an ophthalmologist if they develop ocular symptoms suggestive\nof vitamin A deficiency (e.g., night blindness).\n\nAdverse Reactions \n\nCommonly reported adverse reactions with vutrisiran were injection site\nreactions and increase in blood alkaline phosphatase and alanine transaminase.\n\nFor additional information about vutrisiran, please see the full Summary of\nProduct Characteristics\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Famvuttra-epar-product-information_en.pdf&esheet=54527665&newsitemid=20260504658209&lan=en-US&anchor=Summary+of+Product+Characteristics&index=2&md5=9c07e8d7b051c6b5ed278d7d9f3888b5)\n.\n\nAbout AMVUTTRA(®) (vutrisiran) \n\nAMVUTTRA(® )(vutrisiran) is a transthyretin (TTR) silencer that delivers\nrapid knockdown of TTR at the source to address the underlying cause of\ntransthyretin amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly\nknocked down TTR in as early as six weeks and decreased TTR levels by 87% with\ntwo and a half years of treatment. It is approved as a treatment for the\npolyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in\nadults and for the cardiomyopathy of wild-type or hereditary\ntransthyretin-mediated amyloidosis (ATTR-CM) in adults in various countries,\nglobally. Administered quarterly via subcutaneous injection, AMVUTTRA is the\nfirst and only silencer approved for the treatment of ATTR-CM and hATTR-PN.\n\nAbout Transthyretin Amyloidosis (ATTR) \n\nTransthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive,\ndebilitating, and fatal disease caused by pathogenic transthyretin (TTR)\nproteins, which accumulate as amyloid deposits in various parts of the body,\nincluding the nerves, heart, and gastrointestinal tract. Patients may present\nwith polyneuropathy, cardiomyopathy, or both manifestations of disease. There\nare two different forms of ATTR – hereditary ATTR (hATTR), which is caused\nby a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR\ngene variant. It is estimated that more than 500,000 people worldwide live\nwith ATTR.\n\nAbout RNAi \n\nRNAi (RNA interference) is a natural cellular process of gene silencing that\nrepresents one of the most promising and rapidly advancing frontiers in\nbiology and drug development today. Its discovery has been heralded as “a\nmajor scientific breakthrough that happens once every decade or so,” and was\nrecognized with the award of the 2006 Nobel Prize for Physiology or Medicine.\nBy harnessing the natural biological process of RNAi occurring in our cells, a\nnew class of medicines known as RNAi therapeutics is now a reality. Small\ninterfering RNA (siRNA), the molecules that mediate RNAi and comprise\nAlnylam’s RNAi therapeutic platform, function upstream of today’s\nmedicines by potently silencing messenger RNA (mRNA) – the genetic\nprecursors – that encode for disease-causing or disease pathway proteins,\nthus preventing them from being made. This is a revolutionary approach with\nthe potential to transform the care of patients with genetic and other\ndiseases.\n\nAbout Alnylam Pharmaceuticals \n\nAlnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the\npioneer of the RNA interference (RNAi) revolution. The Company is focused on\ndeveloping transformative therapies with the potential to prevent, halt, or\nreverse disease. For more than two decades, Alnylam has advanced the\nNobel-Prize-winning science of RNAi, delivering critical breakthroughs and six\napproved medicines. Alnylam has medicines available in more than 70 countries\nand a rapidly expanding and robust pipeline, in addition to consistently being\nrecognized as an exceptional workplace and socially responsible organization.\nThe Company is executing on its Alnylam 2030 strategy to accelerate innovation\nand scale impact to transform human health.\n\nAlnylam Forward-Looking Statements \n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934. All statements other than historical statements of fact\nregarding Alnylam’s expectations, beliefs, goals, plans or prospects\nincluding, without limitation, statements regarding the potential for AMVUTTRA\nto be used as a first-line treatment for ATTR-CM; and Alnylam’s ability to\nexecute on its Alnylam 2030 strategy to accelerate innovation and scale impact\nto transform human health, should be considered forward-looking statements.\nActual results and future plans may differ materially from those indicated by\nthese forward-looking statements as a result of various important risks,\nuncertainties and other factors, including, without limitation, risks and\nuncertainties relating to: Alnylam’s ability to successfully execute on its\n“Alnylam 2030” strategy; Alnylam’s ability to successfully launch,\nmarket and sell Alnylam’s approved products globally, including AMVUTTRA;\nAlnylam’s ability to discover and develop novel drug candidates and delivery\napproaches and successfully demonstrate the efficacy and safety of its product\ncandidates; the pre-clinical and clinical results for Alnylam’s product\ncandidates; actions or advice of regulatory agencies and Alnylam’s ability\nto obtain and maintain regulatory approval for its product candidates, as well\nas favorable pricing and reimbursement; delays, interruptions or failures in\nthe manufacture and supply of Alnylam’s marketed products or its product\ncandidates; obtaining, maintaining and protecting intellectual property;\nAlnylam’s ability to manage its growth and operating expenses through\ndisciplined investment in operations; Alnylam’s ability to maintain\nstrategic business collaborations; Alnylam’s dependence on third parties for\nthe development and commercialization of certain products; the outcome of\nlitigation and government investigations; the risk of future litigation and\ngovernment investigations; and unexpected expenditures; as well as those risks\nand uncertainties more fully discussed in the “Risk Factors” filed with\nAlnylam’s 2025 Annual Report on Form 10-K filed with the Securities and\nExchange Commission (SEC), as may be updated from time to time in Alnylam’s\nsubsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam\nmakes with the SEC. In addition, any forward-looking statements represent\nAlnylam’s views only as of today and should not be relied upon as\nrepresenting its views as of any subsequent date. Alnylam explicitly disclaims\nany obligation, except to the extent required by law, to update any\nforward-looking statements.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260504658209/en/\n(https://www.businesswire.com/news/home/20260504658209/en/)\n\nAlnylam Pharmaceuticals, Inc. \n\nChristine Akinc\n\n(Investors and Media)\n\n+1-617-682-4340\n\nJosh Brodsky\n\n(Investors)\n\n+1-617-551-8276\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6PjTCra","title":"Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM","author":"Business Wire","ticker":"ALNY","created":"2026-05-04T12:30:00.404Z","tickers":["ALNY"],"exchange":"NASDAQ","article_body":"Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent\nClinical Profile of Vutrisiran in ATTR-CM\n\nAlnylam Pharmaceuticals, Inc\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.alnylam.com%2F&esheet=54527665&newsitemid=20260504658209&lan=en-US&anchor=Alnylam+Pharmaceuticals%2C+Inc&index=1&md5=4b0af1fd4bf6f61a946eacc825deeeb9)\n. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it\nwill present new data analyses for vutrisiran in patients with the\ncardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis\n(ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society\nof Cardiology, taking place May 9-12, 2026, in Barcelona, Spain.\n\nATTR-CM is a heterogeneous and rapidly progressive disease, and patients often\npresent with complex clinical profiles. At Heart Failure 2026, Alnylam will\npresent multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran,\nwhich continue to support its use as a first-line treatment for patients with\nATTR-CM, and further characterize its clinical profile across patients with a\nhigh disease burden, and in the context of concomitant therapies. Vutrisiran\nis the first and only transthyretin (TTR) silencer for ATTR-CM that delivers\nrapid knockdown of TTR at the source.\n\nAdditional analyses being presented at the congress include a pharmacodynamic\nanalysis of TTR knockdown with vutrisiran across subgroups, a pooled safety\nanalysis evaluating the incidence of TTR lowering with vitamin-A-related\noutcomes across clinical trial and real-world datasets, as well as the design\nof DemonsTTRate, a global, long-term observational study evaluating real-world\nuse in patients with ATTR-CM.\n\nPresentation Details\n\nDesign and Rationale of DemonsTTRate: A Global, Long-Term Observational Study\nto Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with\nCardiomyopathy \n\nSession: Evolving management of cardiomyopathies: early detection, precision\ndiagnostics, and emerging treatments (Moderated ePosters 3)\n\nSunday, May 10, 08:30 – 09:15 CEST, 2:30 – 3:15 A.M. EST\n\nPresenting Author: Pablo Garcia-Pavia, Spain\n\nInfluence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: Insights From\nHELIOS-B \n\nSession: Cardiac amyloidosis: therapeutic strategies and clinical outcomes\n(Moderated ePosters 4)\n\nSunday, May 10, 15:30 – 16:15 CEST, 9:30 – 10:15 A.M. EST\n\nPresenting Author: Awais Sheikh, United Kingdom\n\nEffect of Vutrisiran in Patients with and without Atrial Fibrillation or\nFlutter: Analysis from HELIOS-B \n\nSession: Advances in amyloidosis and hypertrophic cardiomyopathy: from\ndiagnosis to treatment (Moderated ePosters 2)\n\nMonday, May 11, 10:30 – 11:15 CEST, 4:30 – 5:15 A.M. EST\n\nPresenting Author: Xiaowen Wang, United States of America\n\nTreatment with Transthyretin-Lowering RNA Interference Therapeutics is Not\nAssociated with Ocular or Other Clinical Events Due to Vitamin A Reduction:\nPooled Analysis of Vutrisiran and Patisiran Data \n\nSession: Advances in amyloidosis and hypertrophic cardiomyopathy: from\ndiagnosis to treatment (Moderated ePosters 2)\n\nMonday, May 11, 10:30 – 11:15 CEST, 4:30 – 5:15 A.M. EST\n\nPresenting Author: Mathew Maurer, United States of America\n\nVutrisiran-Mediated Knockdown of Transthyretin in Patients with Transthyretin\nAmyloidosis \n\nSession: Transthyretin amyloidosis: long-term outcomes and emerging therapies\n(Rapid Fire Abstracts)\n\nMonday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST\n\nPresenting Author: Vincent Algalarrondo, France\n\nInfluence of Disease-Modifying Therapy on the Effectiveness of Vutrisiran in\nTransthyretin Cardiac Amyloidosis \n\nSession: Transthyretin amyloidosis: long-term outcomes and emerging therapies\n(Rapid Fire Abstracts)\n\nMonday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST\n\nPresenting Author: Arielle Abovich, United States of America\n\nConsistent Efficacy of Vutrisiran Across Sexes in ATTR-CM, HELIOS-B Trial\n–Prespecified Sex Analysis \n\nSession: Transthyretin amyloidosis: long-term outcomes and emerging therapies\n(Rapid Fire Abstracts)\n\nMonday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST\n\nPresenting Author: Josephine Mansell, United Kingdom\n\nComorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights\nFrom the HELIOS-B Trial \n\nSession: Risk factors and comorbidities (Moderated ePosters 3)\n\nTuesday, May 12, 08:30 to 09:15 CEST, 2:30 – 3:15 A.M. EST\n\nPresenting Author: Sarah Birkhoelzer, United Kingdom\n\nAMVUTTRA(®) (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION\n\nIndications \n\nIn the EU, AMVUTTRA(®) (vutrisiran) is indicated for the treatment of:\n\n\n * hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2\npolyneuropathy (hATTR-PN).\n\n * wild-type or hereditary transthyretin amyloidosis in adult patients with\ncardiomyopathy (ATTR-CM).\n\nAvailability across the EU is subject to local reimbursement timelines.\n\nImportant Safety Information \n\nReduced Serum Vitamin A Levels and Recommended Supplementation \n\nVutrisiran treatment leads to a decrease in serum vitamin A levels.\nSupplementation of approximately, but not exceeding, 2500 IU to 3000 IU\nvitamin A per day is advised for patients taking vutrisiran. Patients should\nbe referred to an ophthalmologist if they develop ocular symptoms suggestive\nof vitamin A deficiency (e.g., night blindness).\n\nAdverse Reactions \n\nCommonly reported adverse reactions with vutrisiran were injection site\nreactions and increase in blood alkaline phosphatase and alanine transaminase.\n\nFor additional information about vutrisiran, please see the full Summary of\nProduct Characteristics\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Famvuttra-epar-product-information_en.pdf&esheet=54527665&newsitemid=20260504658209&lan=en-US&anchor=Summary+of+Product+Characteristics&index=2&md5=9c07e8d7b051c6b5ed278d7d9f3888b5)\n.\n\nAbout AMVUTTRA(®) (vutrisiran) \n\nAMVUTTRA(® )(vutrisiran) is a transthyretin (TTR) silencer that delivers\nrapid knockdown of TTR at the source to address the underlying cause of\ntransthyretin amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly\nknocked down TTR in as early as six weeks and decreased TTR levels by 87% with\ntwo and a half years of treatment. It is approved as a treatment for the\npolyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in\nadults and for the cardiomyopathy of wild-type or hereditary\ntransthyretin-mediated amyloidosis (ATTR-CM) in adults in various countries,\nglobally. Administered quarterly via subcutaneous injection, AMVUTTRA is the\nfirst and only silencer approved for the treatment of ATTR-CM and hATTR-PN.\n\nAbout Transthyretin Amyloidosis (ATTR) \n\nTransthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive,\ndebilitating, and fatal disease caused by pathogenic transthyretin (TTR)\nproteins, which accumulate as amyloid deposits in various parts of the body,\nincluding the nerves, heart, and gastrointestinal tract. Patients may present\nwith polyneuropathy, cardiomyopathy, or both manifestations of disease. There\nare two different forms of ATTR – hereditary ATTR (hATTR), which is caused\nby a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR\ngene variant. It is estimated that more than 500,000 people worldwide live\nwith ATTR.\n\nAbout RNAi \n\nRNAi (RNA interference) is a natural cellular process of gene silencing that\nrepresents one of the most promising and rapidly advancing frontiers in\nbiology and drug development today. Its discovery has been heralded as “a\nmajor scientific breakthrough that happens once every decade or so,” and was\nrecognized with the award of the 2006 Nobel Prize for Physiology or Medicine.\nBy harnessing the natural biological process of RNAi occurring in our cells, a\nnew class of medicines known as RNAi therapeutics is now a reality. Small\ninterfering RNA (siRNA), the molecules that mediate RNAi and comprise\nAlnylam’s RNAi therapeutic platform, function upstream of today’s\nmedicines by potently silencing messenger RNA (mRNA) – the genetic\nprecursors – that encode for disease-causing or disease pathway proteins,\nthus preventing them from being made. This is a revolutionary approach with\nthe potential to transform the care of patients with genetic and other\ndiseases.\n\nAbout Alnylam Pharmaceuticals \n\nAlnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the\npioneer of the RNA interference (RNAi) revolution. The Company is focused on\ndeveloping transformative therapies with the potential to prevent, halt, or\nreverse disease. For more than two decades, Alnylam has advanced the\nNobel-Prize-winning science of RNAi, delivering critical breakthroughs and six\napproved medicines. Alnylam has medicines available in more than 70 countries\nand a rapidly expanding and robust pipeline, in addition to consistently being\nrecognized as an exceptional workplace and socially responsible organization.\nThe Company is executing on its Alnylam 2030 strategy to accelerate innovation\nand scale impact to transform human health.\n\nAlnylam Forward-Looking Statements \n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934. All statements other than historical statements of fact\nregarding Alnylam’s expectations, beliefs, goals, plans or prospects\nincluding, without limitation, statements regarding the potential for AMVUTTRA\nto be used as a first-line treatment for ATTR-CM; and Alnylam’s ability to\nexecute on its Alnylam 2030 strategy to accelerate innovation and scale impact\nto transform human health, should be considered forward-looking statements.\nActual results and future plans may differ materially from those indicated by\nthese forward-looking statements as a result of various important risks,\nuncertainties and other factors, including, without limitation, risks and\nuncertainties relating to: Alnylam’s ability to successfully execute on its\n“Alnylam 2030” strategy; Alnylam’s ability to successfully launch,\nmarket and sell Alnylam’s approved products globally, including AMVUTTRA;\nAlnylam’s ability to discover and develop novel drug candidates and delivery\napproaches and successfully demonstrate the efficacy and safety of its product\ncandidates; the pre-clinical and clinical results for Alnylam’s product\ncandidates; actions or advice of regulatory agencies and Alnylam’s ability\nto obtain and maintain regulatory approval for its product candidates, as well\nas favorable pricing and reimbursement; delays, interruptions or failures in\nthe manufacture and supply of Alnylam’s marketed products or its product\ncandidates; obtaining, maintaining and protecting intellectual property;\nAlnylam’s ability to manage its growth and operating expenses through\ndisciplined investment in operations; Alnylam’s ability to maintain\nstrategic business collaborations; Alnylam’s dependence on third parties for\nthe development and commercialization of certain products; the outcome of\nlitigation and government investigations; the risk of future litigation and\ngovernment investigations; and unexpected expenditures; as well as those risks\nand uncertainties more fully discussed in the “Risk Factors” filed with\nAlnylam’s 2025 Annual Report on Form 10-K filed with the Securities and\nExchange Commission (SEC), as may be updated from time to time in Alnylam’s\nsubsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam\nmakes with the SEC. In addition, any forward-looking statements represent\nAlnylam’s views only as of today and should not be relied upon as\nrepresenting its views as of any subsequent date. Alnylam explicitly disclaims\nany obligation, except to the extent required by law, to update any\nforward-looking statements.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260504658209/en/\n(https://www.businesswire.com/news/home/20260504658209/en/)\n\nAlnylam Pharmaceuticals, Inc. \n\nChristine Akinc\n\n(Investors and Media)\n\n+1-617-682-4340\n\nJosh Brodsky\n\n(Investors)\n\n+1-617-551-8276\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-04T12:30:00.460447196Z","server_sent_at_ms":1777897800460},"received_at":"2026-05-04T12:30:00.530Z","source_url":"https://www.businesswire.com/news/home/20260504658209/en/"},"analysis":{"id":"13792","press_release_id":"18991","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Alnylam announced it will present new analyses from the Phase 3 HELIOS-B study for vutrisiran in patients with ATTR-CM at the Heart Failure 2026 congress.\n\nThe presentations highlight a consistent clinical profile and support the use of vutrisiran as a first-line treatment, including in patients with high disease burden or those on concomitant therapies.\n\nAdditional analyses cover pharmacodynamic subgroups, pooled safety data regarding vitamin A, and the design of the long-term observational study DemonsTTRate.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Secondary HELIOS-B analyses reinforce Vutrisiran's first-line positioning in ATTR-CM."},"keyFigures":{"drugName":"vutrisiran","phaseOfTrial":"Phase 3","customDimensions":{"knockdown_timeframe":"six weeks","ttr_knockdown_percent":"87%","global_attr_prevalence":">500,000","approved_medicines_count":6,"vitamin_a_supplement_iu_low":2500,"vitamin_a_supplement_iu_high":3000}},"quotedText":"In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment.","namedEntities":{"people":[{"name":"Pablo Garcia-Pavia","role":"Presenting Author"},{"name":"Awais Sheikh","role":"Presenting Author"},{"name":"Xiaowen Wang","role":"Presenting Author"},{"name":"Mathew Maurer","role":"Presenting Author"},{"name":"Vincent Algalarrondo","role":"Presenting Author"},{"name":"Arielle Abovich","role":"Presenting Author"},{"name":"Josephine Mansell","role":"Presenting Author"},{"name":"Sarah Birkhoelzer","role":"Presenting Author"},{"name":"Christine Akinc","role":"Investors and Media Contact"},{"name":"Josh Brodsky","role":"Investors Contact"}],"products":["AMVUTTRA","vutrisiran","HELIOS-B","DemonsTTRate"],"companies":[{"name":"Alnylam Pharmaceuticals, Inc.","ticker":"ALNY"},{"name":"European Society of Cardiology","relationship":"Congress organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Presentation of secondary analyses from the Phase 3 HELIOS-B study reinforces the commercial narrative for Vutrisiran but does not represent a new primary data readout or regulatory approval."},"tickerRelevance":{"others":[],"primary":"ALNY"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap biotech","eventGravity":"conference-data-presentation","sectorWeight":"health-care"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Alnylam announced it will present new analyses from the Phase 3 HELIOS-B study for vutrisiran in patients with ATTR-CM at the Heart Failure 2026 congress.\n\nThe presentations highlight a consistent clinical profile and support the use of vutrisiran as a first-line treatment, including in patients with high disease burden or those on concomitant therapies.\n\nAdditional analyses cover pharmacodynamic subgroups, pooled safety data regarding vitamin A, and the design of the long-term observational study DemonsTTRate.","key_figures":{"drugName":"vutrisiran","phaseOfTrial":"Phase 3","customDimensions":{"knockdown_timeframe":"six weeks","ttr_knockdown_percent":"87%","global_attr_prevalence":">500,000","approved_medicines_count":6,"vitamin_a_supplement_iu_low":2500,"vitamin_a_supplement_iu_high":3000}},"named_entities":{"people":[{"name":"Pablo Garcia-Pavia","role":"Presenting Author"},{"name":"Awais Sheikh","role":"Presenting Author"},{"name":"Xiaowen Wang","role":"Presenting Author"},{"name":"Mathew Maurer","role":"Presenting Author"},{"name":"Vincent Algalarrondo","role":"Presenting Author"},{"name":"Arielle Abovich","role":"Presenting Author"},{"name":"Josephine Mansell","role":"Presenting Author"},{"name":"Sarah Birkhoelzer","role":"Presenting Author"},{"name":"Christine Akinc","role":"Investors and Media Contact"},{"name":"Josh Brodsky","role":"Investors Contact"}],"products":["AMVUTTRA","vutrisiran","HELIOS-B","DemonsTTRate"],"companies":[{"name":"Alnylam Pharmaceuticals, Inc.","ticker":"ALNY"},{"name":"European Society of Cardiology","relationship":"Congress organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T15:39:26.965Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"large-cap biotech","eventGravity":"conference-data-presentation","sectorWeight":"health-care"}},"durationMs":141552,"modelName":"glm-4.7"}}